Animal Nutrition & Health Enterprise
Start a partner inquiryRequest Grid access
Trail Range Animal Nutrition and HealthRequest Grid access

Products / Trail Tonics / Desert Shield

Trail Tonics · Canine

Desert Shield

A seasonal support concept. This is the category where the distance between market convention and defensible evidence is widest: the ingredient panel is conventional, while the claim language used across the segment sits closest to the regulatory boundary of anything in the portfolio.

SupplementsCanine
Desert Shield concept packaging — a jar and a stand-up pouch labelled “Daily Nutrient Powder” over a “Daily Nutrient Blend” band, with quercetin, colostrum and omega-3 shown as named ingredients without function statements.
4 oz (113 g) — approx. 45 servings · 8 oz (227 g) — approx. 90 servings · 16 oz (454 g) — approx. 181 servings
Crude protein
22.0%minimum, as fed
Crude fat
19.0%minimum, as fed
  • Quercetin at 100 mg a serving against a 25 mg market archetype
  • Bovine colostrum at 250 mg, ten times the common inclusion
  • Ingredients named at stated quantities, without function statements
  • No seasonal or immune claim appears anywhere on this product

Statements of fact about the formula. None is a health claim.

Start a wholesale inquiry

Online ordering opens once distribution is in place. Wholesale and trade enquiries are open now.

Brand
Trail Mutts
Family
Trail Tonics
Category
Supplements
Species
Canine
Commercial status
Concept — not offered for sale
Internal SKU
TRTN-DS-04 · TRTN-DS-08 · TRTN-DS-16
Retail UPC
GS1 assignment pending — one per pack size

Guarantee against formulation

What the label promises, and what the formula delivers

A guarantee is a floor, not a target. The distance between the two is the margin a production run can move within before the label stops being true, and a control fails the build if any formulation ever sits below its own guarantee.

  • Crude Protein

    +3.1 pts22.0% guaranteed · 25.1% delivered

  • Crude Fat

    +3.1 pts19.0% guaranteed · 22.1% delivered

Guaranteed minimum — 22.0% protein, 19.0% fatFormulation delivers — 25.1% protein, 22.1% fatThe guarantee line

The detail

Everything on the panel

Development targets from the working formulation. A guaranteed analysis is derived from assay of finished production batches, and none has been made — so these are the values the formula is built to, not results.

Crude Proteinmin.22.0%
Crude Fatmin.19.0%
Crude Fibermax.22.0%
Moisturemax.8.0%
Quercetin*min.100 mg/serving
Dried Bovine Colostrum*min.250 mg/serving

Not recognised as essential nutrients by the AAFCO Dog Food Nutrient Profiles, and declared here as ingredient quantities rather than as nutrients.

Serving size

1 scoop (2.5 g)

Energy

Approximately 12 kcal per serving

Calculated by the modified Atwater method. Measured values typically run 5–9% higher on dry food, so this is restated once batch data exists.

Nutritional adequacy

Intended for intermittent or supplemental feeding only.

A treat labelled for intermittent or supplemental feeding carries no adequacy statement, because it is not offered as a complete diet.

The panel itself

Read the label, not a description of it

The artwork that goes on the pack, beside the guarantee it carries.

Why this band exists

A buyer comparing two bags is reading label panels. Showing ours at full size, beside the same figures in the table above, is a claim that cannot be made cheaply: it requires the artwork and the specification to already agree.

Where the artwork does not exist yet the band still builds, with a marked placeholder holding the space — so the page keeps one shape across the range and a missing panel reads as pending rather than as a design that broke.

Market role

Trail Tonics — a Trail Mutts family

Supplements are where the evidence is thinnest and the claim ceiling lowest, so the mobility, digestive, skin-and-coat and calm literature is the whole basis for what these may say.

SupplementsCanineBrand family, not a Trail Range line

Trail Range operates development lines and owns brands, and this product sits in a brand. The distinction is kept visible rather than smoothed over: it governs which register the sections below draw on. The brand portfolio sets out the separation.

Formulation direction

What the evidence supports — and what it does not.

Development inputs, not finished formulas. Each candidate is graded on the published evidence, including the ingredients the evidence tells us to leave out.

Mobility support

Sustained comfortable movement in dogs at risk of, or living with, degenerative joint change.

Lead with

  • Energy control and body-condition management

    Established

    The best-evidenced nutritional lever on joint outcomes by a wide margin. Lifetime 25% food restriction pushed median first radiographic hip osteoarthritis from 6 years to 12. In obese dogs, lameness change became detectable from roughly 6% bodyweight loss subjectively and 9% on gait analysis. This is a formulation and feeding-guidance decision, not an additive.

    Basis2006Controlled study2010Controlled study

  • Long-chain omega-3 fatty acids (EPA/DHA)

    Moderate

    The highest-ranked functional ingredient in a 72-trial meta-analysis, and the only nutraceutical a 2012 systematic review found adequately supported in dogs. Whole-diet enrichment raised serum omega-3 and moved owner-assessed function over six months across 18 practices.

    Basis2022Systematic review2021Systematic review

  • Green-lipped mussel lipid extract

    Moderate

    Produced measurable change in force-plate peak vertical force in a blinded, placebo-controlled trial — objective gait data rather than owner impression.

    Basis2023Controlled study

Deprioritise or exclude

  • Glucosamine and chondroitin sulfate

    Counter-indicated

    In the same blinded trial that showed marine lipids moving peak vertical force, glucosamine/chondroitin performed similarly to placebo, and the 2022 meta-analysis reported a marked non-effect. Category convention, not evidence, keeps this pairing in products.

    Basis2022Systematic review2023Controlled study

Claim ceiling. Nutrient contribution and normal structure-function only. Joint or mobility improvement claims name a body system beyond nutritive value and read as drug claims.

Substantiation required. A controlled trial on the finished formula in the target population using validated outcome measures, plus analytical verification and stability data for the active fraction.

Digestive support

Nutrient and protein digestibility, faecal consistency and volume, and hindgut fermentation.

Lead with

  • Fibre matrix — beet pulp and mixed fermentable/insoluble sources

    Moderate

    The strongest evidence in this category sits with fibre rather than microbial ingredients. Beet pulp raised dry matter and total dietary fibre digestibility and lowered wet faecal output versus cellulose and Miscanthus, with a documented trade-off against crude protein digestibility that formulation must balance.

    Basis2026Consensus recommendations2019Controlled study

  • Protein quality and digestibility

    Established

    Consensus veterinary guidance treats diet as the first-line intervention in chronic enteropathy, with hydrolysed and fibre-enriched formulations showing the highest response rates. Formulate on protein quality rather than crude protein alone.

    Basis2006Nutritional standard2026Consensus recommendations

Deprioritise or exclude

  • Probiotics as a headline ingredient

    Emerging

    A systematic review of 17 canine trials found a very limited and possibly clinically unimportant effect with moderate-to-high risk of bias, and consensus panels give probiotics only a weak recommendation. Effects are strain- and dose-specific and cannot be extrapolated between strains, so a named deposited strain with its own data is the minimum bar.

    Basis2019Systematic review2014Consensus recommendations

  • Clinoptilolite for canine digestive support

    Insufficient

    Genuinely promising in neonatal calves, but the canine evidence is close to absent — one unblinded ten-dog study in a non-indexed journal. The one controlled canine microbiota trial used a different zeolite with clinoptilolite absent, and the most rigorous trial against a diarrhoea endpoint in any species missed its primary endpoint.

    Basis2026Regulatory guidance2022Controlled study

Claim ceiling. Nutritive value only. Digestive-health and stool claims name a body system and require pre-market review.

Substantiation required. Controlled canine data on the specific finished formulation, verified viable counts at end of shelf life for any named strain, and defined inclusion levels.

Skin & coat

Substrate supply for keratinisation, hair growth and epidermal integrity.

Lead with

  • Linoleic acid, zinc and protein adequacy

    Established

    Requirements are settled at standards level, and deficiency of any of the three is associated with a dull, scaly or unkempt coat. Adequacy is the foundation; everything else is incremental.

    Basis2006Nutritional standard

  • EPA/DHA

    Moderate

    A systematic review with formal risk-of-bias assessment identified benefit in canine haircoat disorder and allergic dermatitis, though in diseased animals under veterinary management rather than healthy-dog maintenance.

    Basis2021Systematic review2015Consensus recommendations

Deprioritise or exclude

  • Barrier-function positioning

    Insufficient

    A 16-week randomised trial in healthy dogs found graded coat improvement from baseline but no difference between oils and no measurable change in transepidermal water loss — which specifically argues against a skin-barrier claim.

    Basis2023Controlled study

  • Allergy or sensitivity positioning

    Counter-indicated

    Diagnosis of adverse food reaction requires a veterinarian-supervised elimination trial with controlled rechallenge; serological, salivary and hair testing are not reliable. A product named for seasonal or environmental support must never read as an allergy treatment. Ingredient verification testing matters here regardless: a median 45% of commercial foods tested contained unlisted ingredients.

    Basis2018Systematic review2025Consensus recommendations

Claim ceiling. Nutrient contribution to normal skin and coat. No allergy, dermatitis or barrier-repair language.

Substantiation required. Formulation records against published requirements, analytical ingredient verification, and a controlled coat-scoring study on the finished product.

Calm-behavior nutrition

Precursor and cofactor supply to pathways implicated in stress physiology.

Lead with

  • L-tryptophan

    Emerging

    The best-supported option in a thin field, and only as an adjunct. Appraised evidence rests on two adequately designed low-risk-of-bias studies and supports a supporting role alongside behavioural management — the authors state explicitly it is not enough as a sole intervention.

    Basis2024Systematic review

Deprioritise or exclude

Claim ceiling. This is the sharpest regulatory hazard in the portfolio. Anxiety is a recognised disease state, so calming language can move a food toward unapproved new animal drug status. Treat as nutrient contribution only.

Substantiation required. A randomised, blinded, placebo-controlled trial on the finished formulation with validated behavioural and physiological endpoints, plus ingredient safety at the fed dose.

Performance and working-dog nutrition

Work capacity, thermal tolerance and inter-session recovery in dogs performing repeated physical work.

Lead with

  • Energy density and fat level matched to work type

    Established

    Energy demand dominates and is context-dependent — measured requirements in racing endurance dogs ranged from roughly 9,000 to an extrapolated 13,800 kcal/day between race legs, driven by load, terrain and temperature rather than distance. Higher fat suits endurance work; balanced macronutrients suit sprint work.

    Basis2014Consensus recommendations

  • Palatable oral electrolyte for voluntary intake

    Moderate

    A flavoured electrolyte solution more than doubled voluntary fluid intake versus plain water in working detection dogs in a hot environment, making palatability-driven intake a legitimate design objective in its own right.

    Basis2017Controlled study

Deprioritise or exclude

  • Performance or thermoregulatory claims from hydration

    Insufficient

    The same trial that doubled voluntary intake detected no effect on core body temperature or olfactory search performance. Intake is the demonstrated outcome; performance is not.

    Basis2017Controlled study

Claim ceiling. Nutrient and energy contribution. No performance, endurance or recovery outcome claims.

Substantiation required. Energy density and digestibility data, a controlled feeding trial in the intended working population with objective work and recovery endpoints, and field voluntary-intake data.

Every brief covering Trail Range Professional is shown rather than only those bearing on this product, because a brief is a development input for a category and not a statement about one item. Narrowing it further needs a per-product category on the record.

Evidence map

The sources this product answers to — with their limits visible.

These sources guide standards, ingredient review and study design. They do not automatically substantiate an unfinished product.

Register: Trail Range Professional · Supplements are where the evidence is thinnest and the claim ceiling lowest, so the mobility, digestive, skin-and-coat and calm literature is the whole basis for what these may say.

10 sources · 2025 back to 2006

2025 · Nutritional standard

Reading labels — nutritional adequacy statement formats

Association of American Feed Control Officials

Scope. Required label elements, the standardized nutritional adequacy statement formats, and what constitutes misbranding.

Supports. Gives the exact prescribed wording for each substantiation route and confirms that an incorrect adequacy statement, or a disease claim without an approved drug, is misbranding.

Does not establish. Does not carry force of law on its own — AAFCO models bind only where a state has adopted them, and AAFCO approves, certifies and endorses nothing.

Primary source ↗

2023 · Controlled study

Effectiveness of glucosamine and chondroitin sulfate, marine-based fatty acid compounds, and carprofen in dogs with hip osteoarthritis

Frontiers in Veterinary Science

Scope. Six-week block-randomised, double-blinded, placebo-controlled trial in 75 owned dogs measured against force-plate peak vertical force.

Supports. Objective gait evidence that marine lipid extracts can shift weight-bearing, and that glucosamine/chondroitin at 30 mg/kg/day performed similarly to placebo.

Does not establish. Does not extend beyond six weeks, found no significant between-group difference on subjective scoring, and was supported by a supplement manufacturer.

Primary source ↗

2022 · Systematic review

Systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis

Université de Montréal / International Journal of Molecular Sciences

Scope. Screened 1,578 publications and pooled 72 trials across nine categories of natural health compound in dogs and cats with osteoarthritis.

Supports. Ranks long-chain omega-3 fatty acids as the lead functional ingredient by effect size, and de-prioritises glucosamine–chondroitin.

Does not establish. Does not validate any commercial formulation; the authors flag subjective outcome tools, groups often under ten animals, and wide variation in dose and duration.

Primary source ↗

2021 · Systematic review

Therapeutic effect of EPA/DHA supplementation in neoplastic and non-neoplastic companion animal diseases: a systematic review

In Vivo

Scope. Systematic review of randomised controlled EPA/DHA studies in dogs and cats with Cochrane RoB2 risk-of-bias assessment; 23 studies included.

Supports. Identifies benefit in canine allergic dermatitis and haircoat disorder among included trials — the strongest single citation for an EPA/DHA coat rationale.

Does not establish. Does not establish effect size, dose or duration for a healthy-dog maintenance product; benefit was found in diseased animals under veterinary management.

Primary source ↗

2019 · Systematic review

Clinical effect of probiotics in prevention or treatment of gastrointestinal disease in dogs: a systematic review

Journal of Veterinary Internal Medicine

Scope. Screened 165 studies, including 17 in vivo canine trials, grading design quality and risk of bias; stool consistency was the most reported outcome.

Supports. Establishes stool consistency as the practical primary outcome for canine digestive research and the need for strain-level data.

Does not establish. Does not support a general probiotic efficacy claim in dogs — the authors found a very limited and possibly clinically unimportant effect, with moderate-to-high risk of bias throughout.

Primary source ↗

2019 · Controlled study

Effects on nutrient utilization and stool quality of Beagle dogs fed diets with beet pulp, cellulose and Miscanthus grass

Journal of Animal Science / Kansas State University

Scope. Replicated Latin square in 12 Beagles comparing three fibre sources at 10% inclusion with total faecal collection.

Supports. Quantifies the fibre trade-off directly: beet pulp raised dry matter and total dietary fibre digestibility and lowered wet faecal output versus cellulose and Miscanthus.

Does not establish. Does not demonstrate a clinical gut-health benefit; beet pulp also lowered crude protein digestibility and produced softer stools, in 12 healthy laboratory dogs at one inclusion level.

Primary source ↗

2017 · Controlled study

Evaluation of three hydration strategies in detection dogs working in a hot environment

Frontiers in Veterinary Science

Scope. Randomised cross-over field study in seven working dogs comparing plain water, flavoured oral electrolyte solution and subcutaneous fluids.

Supports. Shows flavoured electrolyte solution more than doubled voluntary fluid intake versus water, making palatability-driven intake a legitimate design objective.

Does not establish. Does not demonstrate any performance or thermoregulatory benefit — no effect was detected on body temperature or search performance.

Primary source ↗

2014 · Consensus recommendations

Nutrition for working and service dogs

Veterinary Clinics of North America: Small Animal Practice

Scope. Review of nutritional physiology across canine work types, covering dietary fat, glycogen repletion, protein and ageing working dogs.

Supports. The macronutrient design logic for work-type-specific formulation — higher fat for endurance, balanced macronutrients for sprint work, post-exercise carbohydrate for repeated efforts.

Does not establish. Does not rest on trial evidence for all work types; the authors state that studies for agility, field-trial and detection dogs are rare, so those recommendations are extrapolated.

Primary source ↗

2006 · Nutritional standard

Nutrient Requirements of Dogs and Cats

National Research Council / National Academies Press

Scope. Consensus requirements, adequate intakes and recommended allowances for every essential nutrient in dogs and cats, across life stages.

Supports. The quantitative floor and ceiling for formulating canine diets and complementary products.

Does not establish. Does not establish requirements, doses or efficacy for probiotics, prebiotics, postbiotics, glucosamine, collagen or any other non-essential ingredient.

Primary source ↗

2006 · Controlled study

Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs

Journal of the American Veterinary Medical Association

Scope. Lifetime paired-littermate study in 48 Labrador Retrievers fed either ad libitum or 25% less of the same diet from eight weeks of age.

Supports. Establishes lifetime energy control as the best-evidenced nutritional lever on joint outcomes — median age at first radiographic osteoarthritis 12 years restricted versus 6 years control.

Does not establish. Does not test any supplement or functional ingredient, uses radiographic rather than pain endpoints, and studied one breed in a controlled colony.

Primary source ↗

Rest of the line

Trail Tonics

Mesa Microbiome supplied packaging concept

Mesa Microbiome

Supplements · Canine

High Desert Coat supplied packaging concept

High Desert Coat

Supplements · Canine

Camp Calm concept packaging — a jar and a stand-up pouch carrying a “Relaxation + Stress Support” band above L-theanine, chamomile and magnesium ingredient icons with function lines beneath each.

Camp Calm

Supplements · Canine

Documentation

What a buyer can ask for

Three documents, and the state each is actually in. A buyer asking “what can you send me?” wants the answer as a list of things they can request, not as a status band they have to interpret.

Available now

Specification packet

Formulation, guarantees, the acceptance windows each is judged against and the regulatory edition in force, with a revision hash so two copies can be told apart.

Available now

Claim sheet

Every claim the label makes, the basis for each one, and — the part buyers rarely get — the terms we have deliberately not used, with the reason.

On manufacture

Certificate of analysis

Per lot, assayed against the acceptance windows above. Available once a production run exists — which is also when the guaranteed analysis stops being a target and becomes a result.

Documentation statusSpecified

Formulation, guaranteed analysis, ingredient statement and label copy are documented, and the figures are checked against each other automatically rather than by proofreading.

Documented

  • Formulation recorded, and every guarantee is checked against what the formula actually delivers — a minimum above the formulation value cannot hold on assay.
  • Ingredient statement written in descending order by weight using AAFCO ingredient names.
  • Guaranteed analysis specified.
  • Serving size, pack sizes and feeding directions specified.
  • Print-ready panel copy written — front panel, ingredient statement, guaranteed analysis and directions, section 15 of the label copy deck.
  • Internal SKU assigned, one per saleable pack.

Not yet established

  • No production batch has been made. A guaranteed analysis is derived from assay of finished batches — mean − 2 SD for minima, mean + 2 SD for maxima — so every figure shown is the value the formula is built to, not a verified result.
  • Retail GTIN-12 pending. A UPC must be licensed from GS1 under the registered brand owner; internal SKUs are not substitutes and are not scannable.
  • Supplied packaging artwork is concept art. Names, claims, formats and sizes shown on an image are not approved product facts.

Claim ceiling: Composition may be stated; effect may not. An article intended to affect the structure or function of the body, otherwise than by nutrition, is a drug under 21 U.S.C. § 321(g)(1)(C), and “support” does not soften a function claim — it is the word that most reliably creates one. What a buyer may be told is ingredient identity and inclusion level, and for anything live, viable count at the end of shelf life rather than at manufacture. Immune language carries two exposures at once: it makes the product a drug under the FDCA, and a product presented as acting through the immune system is a USDA veterinary biologic under 9 CFR 101.2 rather than a feed. Seasonal and environmental phrasing does not avoid this — it describes the same claim in gentler words. The concept artwork was corrected on 2 August 2026 to remove every function line for this reason.